OKUR

Analyst Rating Changes: Various Wall Street analysts have adjusted their price targets for several companies, with Citigroup lowering AvePoint's target from $18 to $16 while maintaining a Neutral rating, and BMO Capital raising Protagonist Therapeutics' target from $62 to $72 with an Outperform rating.

Stock Performance Updates: Other notable changes include Stifel cutting DarioHealth's target to $2 but keeping a Buy rating, and Morgan Stanley increasing Gilead Sciences' target to $130 while maintaining an Overweight rating.

OnKure Therapeutics (OKUR): Analyst Matthew Biegler maintains a Buy rating with a price target of $30.00, despite the stock currently trading near its 52-week low; the consensus rating is a Moderate Buy with an average target of $31.00.

EyePoint Pharmaceuticals (EYPT): Analyst Tyler Van Buren also holds a Buy rating with a price target of $20.00, while the overall analyst consensus suggests a Strong Buy with a significant upside potential to an average target of $33.83.

PIKture-01 Trial Updates: OnKure Therapeutics is set to provide additional data from the PIKture-01 trial, including safety and pharmacokinetic results for its lead drug OKI-219, with updates expected in the second half of 2025. The company has also initiated a combination study with fulvestrant and plans to announce a new pan-mutant selective program by Q2 2025.

Financial Overview: As of December 31, 2024, OnKure reported approximately $110.8 million in cash, sufficient to fund operations through multiple clinical readouts into Q4 2026. The company experienced increased R&D expenses and reported a net loss of $17.4 million for the fourth quarter of 2024.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

Biotech Study Insights: Analysts Watsek & Schimmer discuss findings from LLY's EMBER-3 study and their implications for ARVN's VERITAC-2 trial, along with results from ARVN’s TACTIVE-U Phase 1 trial and data from BCYC, RLAY, and OKUR, to be presented in an upcoming conference call.

Stock Recommendations: The article highlights the importance of identifying top-rated stocks recommended by analysts to maximize investment portfolios, including recent analyst calls on companies like eBay and GM.

Clinical Trial Results: OnKure Therapeutics reported positive safety and tolerability results from the first-in-human study of their drug OKI-219, with only mild treatment-related adverse events observed, supporting further development.

Future Plans: The company plans to present new preclinical data at the 2024 San Antonio Breast Cancer Symposium and is set to initiate Part 1b of the PIKture-01 trial for OKI-219 in combination with fulvestrant, aiming for more comprehensive data by late 2025.

Clinical Trial Results: OKI-219, a selective PI3Kα inhibitor, has shown promising safety and tolerability in an ongoing trial with no dose interruptions or serious adverse events reported. Initial patient data indicate effective drug exposure levels that align with preclinical antitumor activity.

Future Developments: The company plans to advance the PIKture-01 trial into Part 1b, evaluating OKI-219 in combination with fulvestrant, with initial results expected in the second half of 2025. Additionally, OnKure is expanding its pipeline to target various PI3Kα mutations for enhanced cancer treatment options.

Company Overview and Changes: Reneo Pharmaceuticals has rebranded to OnKure Therapeutics following a merger, focusing on precision cancer therapies and utilizing a computational chemistry-driven design platform.

Financial Performance and Outlook: The latest earnings report shows a reduced net loss of $17.5 million for the first nine months of 2024, down from $53.8 million in 2023, with a successful private placement raising $65 million to support future operations and development.

OnKure Therapeutics Announcement: OnKure Therapeutics will present preliminary data from its first-in-human PIKture-01 trial of OKI-219 at the 2024 San Antonio Breast Cancer Symposium, with an investor call scheduled for December 10, 2024.

Clinical Trial Details: The PIKture-01 study investigates OKI-219, a selective PI3KαH1047R inhibitor, in patients with advanced solid tumors and breast cancer, aiming to enhance treatment efficacy through combination therapies.

Integration Challenges: Onkure Therapeutics, Inc. is facing significant difficulties in merging Reneo and Legacy OnKure, which may hinder expected benefits due to the need for extensive management resources and potential unforeseen liabilities.

Talent Competition: The company struggles to attract and retain high-quality personnel due to competition from established biotechnology firms offering better compensation and career opportunities, impacting its innovation and growth capabilities.

Corporate Presentation Announcement: OnKure Therapeutics, Inc. will present a corporate overview at the Stifel Healthcare Conference on November 18, 2024, at 1:50 p.m. ET, which will be available via live webcast and replay on their website.

Company Focus and Pipeline: OnKure is a clinical-stage biopharmaceutical company developing precision medicines for oncology, with its lead program being OKI-219, a selective PI3Kα inhibitor, aimed at targeting underserved cancer therapies.

Real-time Trading Intelligence: Benzinga Pro offers the fastest news alerts and real-time intelligence for traders to enhance their market performance.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and accurate stock market insights.

OnKure Therapeutics Merger and Analyst Coverage: OnKure Therapeutics completed its merger with Reneo Pharmaceuticals, raising $65 million in a private placement, and has been given an Outperform rating by analysts with a price target of $35, highlighting the potential of its drug OKI-219 for treating specific breast cancer mutations.

Market Potential and Competitive Landscape: The analyst notes that while alpelisib currently generates around $500 million in annual sales, there is significant market potential exceeding $1 billion due to the prevalence of PI3Kα mutations in breast cancer, suggesting that OKI-219 could address limitations seen in existing treatments.

Analyst Ratings Changes: Several Wall Street analysts have initiated coverage on various companies, including Align Technology (Hold), SiteOne Landscape Supply (Neutral), OnKure Therapeutics (Outperform), IperionX Limited (Buy), and Builders FirstSource (Buy) with respective price targets announced.

Stock Performance: Following the ratings changes, Align Technology, SiteOne Landscape Supply, and OnKure Therapeutics saw declines in their stock prices, while Builders FirstSource experienced a slight increase.